Uncategorized

Merck’s Welireg combo fails in first-line kidney cancer

Published

4 hours ago

on

Adding Merck’s Welireg to an existing Keytruda regimen didn’t lead to a significant improvement in newly diagnosed patients with advanced kidney cancer, Merck announced on Tuesday.

The results mark a setback …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version